$GYRE
Gyre Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$6.08
▼-5.00%-$0.320
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateGyre Therapeutics, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is GYRE down today? It is at $6.08 (-5.00%), and our scanner flagged it 14 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment GYRE spikes, and full due diligence on GYRE — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $GYRE 14 times in the last 30 days. Create a free account to track $GYRE, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on GYRE from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for GYRE today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalyst1 September 2026 A Global Innovator Expanding And Reinventing Protein DegraderReported oncology/I&I DACs in pre-IND studies ETUARYTM FY26 Total Revenue Guidance $100.5M-$111M F351 potential launch in early 27’ San Diego: Headquarters Shanghai: Discovery Beijing: Manufacturing & Sales *TPDs = targeted proteinReported Prevalence (%) [1] Market Opportunity & Unmet Medical Need Verzenio, Kisqali, and Ibrance ~$14.6B Total Global Revenues in 2025 Projected total global revenues between $25.8B - $35.7B by early 2030s ~50% of patients developReported 330K 70-90% develop symptomatic pain with limited current treatment options 3 Significant Unmet Need Average treatment duration for cancer-induced bone pain 4,5 193-225 Days CDK2 / Cyclin E TYK2 /, from the latest SEC filing. Read it →The company is cleared to issue new shares on demand, but has not yet. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Active shelf on file — the company can issue new shares on demand (valid ~3 years)
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Ye Weiguo Officer | Sold (automatic/other) | -3K | sold 0.4% | 700K | $19K at $6.35 | Jun 18, 26 |
Ye Weiguo Officer | Other | 3K | added 0.4% | 703K | $2K at $0.750 | Jun 18, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -3K | sold 0.4% | 700K | $17K at $6.17 | Jun 11, 26 |
Ye Weiguo Officer | Other | 3K | added 0.4% | 703K | $2K at $0.750 | Jun 11, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -6K | sold 0.9% | 700K | $40K at $6.21 | Jun 10, 26 |
Ye Weiguo Officer | Other | 6K | added 0.9% | 706K | $5K at $0.750 | Jun 10, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -5K | sold 0.7% | 700K | $31K at $6.24 | Jun 10, 26 |
Ye Weiguo Officer | Other | 5K | added 0.7% | 705K | $4K at $0.750 | Jun 10, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -15K 0.01% of company | sold 2.0% | 700K | $89K at $6.14 | Jun 9, 26 |
Ye Weiguo Officer | Sold (automatic/other) | -3K | sold 0.4% | 700K | $18K at $6.15 | Jun 9, 26 |
Ye Weiguo Officer | Other | 15K 0.01% of company | added 2.1% | 715K | $11K at $0.750 | Jun 9, 26 |
Ye Weiguo Officer | Other | 3K | added 0.4% | 703K | $2K at $0.750 | Jun 9, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on GYRE from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for GYRE today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
GYRE last traded at $6.08, down 5.00% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Gyre Therapeutics, Inc. Common Stock (GYRE) is next expected to report earnings on Friday, November 6, 2026, about 21 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The GYRE Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged GYRE 14 times in the last 30 days.
GYRE (Gyre Therapeutics, Inc. Common Stock) trades on XNAS, with a market cap of about $714M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge GYRE for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$GYRE discussion
Sign in to ask a question or join the discussion.